A Parallel Group, Phase 1 b, Double-blind, Placebo-controlled, Four-arm Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous BRN-002 Compared with Placebo in Male and Female Healthy Adult Participants
Latest Information Update: 15 Mar 2022
At a glance
- Drugs Hydroxypropyl betadex (Primary)
- Indications Atherosclerosis
- Focus Adverse reactions
- Sponsors Beren Therapeutics
Most Recent Events
- 15 Mar 2022 New trial record